**Name of Journal: *World Journal of Gastrointestinal Endoscopy***

**ESPS Manuscript NO: 27261**

**Manuscript Type: Original Article**

***Retrospective Study***

**Outcomes of submucosal (T1b) esophageal adenocarcinomas removed by endoscopic mucosal resection**

Ballard DD *et al.* Submucosal esophageal adenocarcinomas removed by EMR

**Darren D Ballard, Neel Choksi, Jingmei Lin, Eun-Young Choi, B Joseph Elmunzer, Henry Appelman, Douglas K Rex, Hala Fatima, William Kessler, John M DeWitt**

**Darren Ballard,** Division of Gastroenterology and Hepatology, Medical College of Wisconsin, Milwaukee, WI 53226, United States

**Neel Choksi**, Division of Gastroenterology, University of Michigan, Ann Arbor, MI 48109, United States

**Jingmei Lin,** Department of Pathology, Indiana University, Indianapolis, IN 46202, United States

**Eun-Young Choi,** Department of Pathology, University of Michigan, Ann Arbor, MI 48109, United States

**Badih Elmunzer,** Division of Gastroenterology and Hepatology, University of South Carolina, Charleston, SC 29425, United States

**Henry Appelman,** Department of Pathology, University of Michigan, Ann Arbor, MI 48109, United States

**Douglas Rex,** **Hala Fatima, William Kessler, John DeWitt,** Division of Gastroenterology and Hepatology, Indiana University, Indianapolis, IN 46202, United States

**Author contributions:** Ballard DB and DeWitt JM designed the research; Ballard DB, Choski N, Lin J, Choi E, Elmunzer BJ, Appelman H, Rex DK, Fatima H, Kessler W and DeWitt JM performed the research; Ballard DB and DeWitt JM analyzed the data; Ballard DB and DeWitt JM wrote the manuscript; Choski N, Lin J, Choi E, Elmunzer BJ, Appelman H, Rex DK, Fatima H and Kessler W critically reviewed the manuscript.

**Institutional review board statement:** The study was reviewed and approved by the IRB at Indiana University and the University of Michigan.

**Informed consent statement:** No informed consent was required as this was a retrospective study approved by the IRB.

**Conflict-of-interest** **statement:** There are no conflicts of interest for any of the authors of this study.

**Data sharing statement:** Dataset is available from the corresponding author at [dballard@mcw.edu](mailto:dballard@mcw.edu).

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Correspondence to:** **Darren D Ballard, Assistant Professor,** Division of Gastroenterology and Hepatology, Medical College of Wisconsin, 9200 W Wisconsin Ave, Milwaukee, WI 53226, United States. [dballard@mcw.edu](mailto:dballard@mcw.edu)

**Telephone:** +1-414-9556821

**Fax** +1-414-9556215

**Received:** May 20, 2016

**Peer-review started:** May 20, 2016

**First decision:** July 20, 2016

**Revised:** August 23, 2016

**Accepted:** September 13, 2016

**Article in press:**

**Published online:**

**Abstract:**

***AIM***

To investigate the outcomes and recurrences of pT1b esophageal adenocarcinoma (EAC) following endoscopic mucosal resection (EMR) and associated treatments.

***METHODS***

Patients undergoing EMR with pathologically confirmed T1b EAC at two academic referral centers were retrospectively identified. Patients were divided into 4 groups based on treatment following EMR: endoscopic therapy alone (group A), endoscopic therapy with either chemotherapy, radiation or both (group B), surgical resection (group C) or no further treatment/lost to follow up (< 12 mo) (group D). Pathology specimens were reviewed by a central pathologist. Follow up data was obtained from the academic centers, primary care physicians and/or referring physicians. Univariate analysis was performed to identify factors predicting recurrence of EAC.

***RESULTS***

Fifty-three patients with T1b EAC underwent EMR, of which 32 (60%) had adequate follow up ≥ 12 mo (median 34 mo, range 12-103). There were 16 patients in group A, 9 in group B, 7 in group C and 21 in group D. Median follow up in Groups A to C was 34 mo (range 12-103). Recurrent EAC developed overall in 9 patients (28%) including 6 (38%) in group A (median: 21 mo, range: 6-73), 1 (11%) in group B (median: 30 mo, range: 30-30) and 2 (29%) in group C (median 21 mo, range: 7-35. Six of 9 recurrences were local; of the 6 recurrences, 5 were treated with endoscopy alone. No predictors of recurrence of EAC were identified.

***CONCLUSION***

Endoscopic therapy of T1b EAC may be a reasonable strategy for a subset of patients including those either refusing or medically unfit for esophagectomy.

**Key words:** Esophageal cancer; Submucosal; T1b; Endoscopic mucosal resection; Chemotherapy; Esophagectomy

**© The Author(s) 2016.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Endoscopic eradication therapy (EET) is reported as safe and effective for low risk T1b esophageal adenocarcinomas (EAC), but overall data is lacking. We retrospectively evaluated patients with T1b EAC treated with EET, EET with chemotherapy and/or radiation therapy and surgical resection. The overall recurrence rate was 28% at median 21 months (range: 6-73) following EMR. In those treated with EMR alone, recurrence rate was 38% at median 21 months (range: 6-73). Six of the 9 recurrences were local; 5 were treated with endoscopy alone. EET of T1b EAC may be a reasonable treatment strategy for a subset of these patients.

Ballard DB, Choksi N, Lin J, Choi E, Elmunzer BJ, Appelman H, Rex DK, Fatima H, Kessler W, DeWitt JM. Outcomes of submucosal (T1b) esophageal adenocarcinomas removed by endoscopic mucosal resection. *World J Gastrointest Endosc* 2016; In press

**INTRODUCTION**

Due to the inherent morbidity and rare mortality associated with esophagectomy and lymph node dissection, endoscopic eradication therapy [including endoscopic mucosal resection (EMR) and ablative techniques] has been increasingly used as a safe, effective and potentially curative organ-sparing procedure to treat high grade dysplasia (Tis lesions) and intramucosal esophageal cancer (T1a lesions)[1-5]. When complete resection or eradication of T1a cancers is confirmed, disease is generally considered cured due to the low rate of reported lymph node metastasis (< 2%) in these patients[6]. Tumors that penetrate the submucosa of the esophagus (T1b cancers), however metastasize to regional lymph nodes in up to 30% of cases and the likelihood for metastases increases the further the tumor penetrates from the first third (sm1) into the lower two thirds (sm1 and sm2) of the submucosal layer[7-11]. Therefore, endoscopic eradication therapies (EET) have generally not been employed in patients with T1b cancers.

The use of EET for primary treatment of T1b tumors was initially reported in patients with “low risk” submucosal esophageal cancers (macroscopically polypoid or flat, invasion limited to the upper 1/3 of the submucosa, no invasion of the vessels or lymphatic system, well to moderate tumor differentiation); this has more recently been updated in a larger series (*n* = 66) from the same group with similar characteristics showing recurrent or metachronous carcinomas developed in 19% of patients with an estimated 5 year survival rate of 84%[12,13]. A study from two referral centers in the Netherlands examined EET of deep T1a and T1b EAC (*n* = 75) with an overall recurrence rate of 9%[14]. A study from a tertiary center in the United States reported a group of patients (*n* = 29) with T1b EAC with sm1 (46%) and sm2-3 (54%) invasion that underwent either EET, chemo/radiation or a combination of both and showed mean survival of 34.8 mo with a 38% mortality rate[15].

To our knowledge, there are no studies examining the outcomes and predictors of disease recurrence in patients with pathologically staged T1b esophageal cancer treated with EET alone, surgery, or adjuvant therapy following endoscopic resection. Identification of predictive factors for recurrence and outcomes following endoscopic therapy in this population would help to identify and tailor appropriate treatment. For this reason, we aimed to (1) retrospectively evaluate the clinical outcomes of pT1b esophageal cancers following EMR; (2) to compare the recurrence rates of cancer when patients are treated with EET alone, EET in association with chemotherapy, radiation therapy or both and surgical resection; and (3) to evaluate the predictors of recurrence of T1b esophageal cancer following EMR.

**MATERIALS AND METHODS**

***Study population and design***

All patients age ≥ 18 years of age who underwent EMR of the esophagus from 2001 to 2013 at Indiana University Medical Center and the University of Michigan were retrospectively identified from institutional endoscopic databases. Patient charts were then reviewed to identify the subset of patients with pathologically (p) staged T1b esophageal cancer that comprised the study population. Patients with treatment by endoscopic submucosal dissection or ≤ 12 mo of follow up after resection were excluded. Approval for this study was obtained by the institutional review boards at both participating institutions prior to any study activities.

Pre-procedure imaging with CT and/or PET scans was initially obtained in all patients to exclude distant metastasis. EUS was also used in selected patients to assess the depth of any visualized mass or detect and sample any suspicious lymph nodes. Prior to EMR, all patients underwent EGD with a detailed exam of the mucosa of the esophagus and gastric cardia. The use of advanced imaging techniques such as narrow band imaging and chromoendoscopy was at the discretion of the endoscopist. After identification of the site(s) for resection, either cap-assisted (Olympus America Inc., Center Valley, PA) or band ligation-assisted EMR (Cook Medical Inc., Winston Salem, NC) was performed. The specimens retrieved were placed into formalin and sent to pathology for evaluation for examination by an experienced gastrointestinal pathologist.

***Treatment groups***

Treatment after identification of a pT1b esophageal cancer at each institution was at the discretion of the endoscopist as well as referring physicians based on the pathology findings, patient comorbidities and patient wishes. For study purposes, treatment after EMR was classified as utilizing endoscopy alone (Group A), endoscopy with either chemotherapy, radiation or both (Group B), surgical resection alone (Group C), or no further treatment or lost to follow-up (Group D). Patients in group A underwent additional EMR with or without ablation, surveillance endoscopies and cross-sectional imaging as determined by the treating physicians.

***Pathology assessment***

Endoscopic resection specimens from both institutions were initially reviewed by local pathologists. For the current study, slides from both institutions were re-reviewed by a single gastrointestinal pathologist at Indiana University for the following characteristics: depth of tumor invasion (sm1 *vs* sm2/3), tumor differentiation (well, moderate and poor), presence or absence of lymphatic or perineural invasion (LPI) and the status of deep and lateral margins following resection. A T1b esophageal cancer was defined as tumor extending beyond the muscularis mucosa and into tissue which contains submucosal glands or tumor adjacent to large caliber arteries which would not be present in the mucosa. Tumors classified as sm1 had invasion of tumor into the upper 1/3 of the submucosa and sm2/3 depth of invasion was defined as invasion into the lower 2/3 of the submucosa. Tumor differentiation was determined based on standard histologic features such as growth pattern, gland formation and degree of atypia. LPI was defined as the presence of malignant tumor cells within a lymphatic channel or neural bundle.

***Follow-up***

Follow-up cross-sectional imaging and endoscopy were performed at the discretion of the endoscopist and consulting physicians at each institution. These data on the study population were obtained both from the treating institution as well as referring physicians and primary care physicians and consisted of endoscopic procedures, imaging studies and clinic visits. The end point of follow up for study patients included: death, surgery for esophageal cancer, or loss of patient contact. Patient death was identified by reviewing medical records or by searching the Social Security Death Index. Tumor recurrence was diagnosed when biopsies from the previous or adjacent esophageal EMR site or from either regional or metastatic sites demonstrated pathology consistent with the primary cancer. A univariate analysis was performed in order to identify factors predicting recurrence of cancer after EMR and associated treatment. Variables analyzed in the analysis included: method of EMR (cap *vs* band), pathology depth (sm1 *vs* sm2/3), initial tumor location (proximal 2/3 *vs* distal 1/3 of the esophagus), lymphovascular and/or perineural invasion, degree of tumor differentiation, positive *vs* negative deep and lateral EMR margins, and primary treatment modality (endoscopic ± chemotherapy and/or radiation therapy *vs* surgery).

***Statistical analysis***

The data were analyzed descriptively using means, medians, ranges and standard deviations. The variables between groups were compared using Fisher’s exact tests (GraphPad). *P* < 0.05 was considered statistically significant.

**RESULTS**

Sixty patients who underwent EMR were found to have pT1b esophageal cancer, including 53 with (88%) adenocarcinoma and 7 (12%) squamous cell carcinoma. Of the 53 patients with adenocarcinomas, 32 patients (60%) had adequate follow up after EMR of ≥ 12 mo (median 34 mo, range 12-103). There were 16 patients in group A, 9 patients in group B, 7 patients in group C and 21 patients in group D (8 with no further treatment and 13 without required 12 mo follow-up). Demographics, EMR method (cap *vs* band), pathology findings and follow-up are summarized in Table 1. Pathology in patients who underwent esophagectomy (group C) showed no residual dysplasia or malignancy in 2, adenocarcinoma with negative nodes in 1, dysplasia in 3 and 1 with unknown findings.

No recurrence of carcinoma developed in 23 patients (72%) during a median follow-up of 31 mo (range 12-103). Recurrent adenocarcinoma developed in 9 (28%) patients among all 3 groups. There was no statistically significant differences between recurrences in group A (*n* = 6; 38%), group B (*n* = 1; 11%) and group C (*n* = 2; 29%). Median time to recurrence was 21 mo (range 6-73) in group A, 30 mo in group B, and 9 mo (range 8-10) in group C. Of the recurrences in group A, 5 were local and 1 was metastatic. These local recurrences in group A were treated with further EET alone in two, EET and radiation in one, EET with chemotherapy with radiation in one and radiation in one. The single metastatic recurrence in group A was treated with chemotherapy and radiation. The single recurrence in group B was metastatic and had no further treatment. The two recurrences in group C were local in one and metastatic in one. The local recurrence in group C was treated with chemotherapy and the metastatic recurrence in group C was treated with local resection of a hepatic metastasis. No predictors of recurrence of adenocarcinoma were identified on univariate analysis (Table 2).

Of the 32 patients in groups A, B and C, 7 died within 3 years of EMR giving an overall 3 year mortality for all causes of 22%. Specifically within each group, 3 year mortality rates were 13% in group A (2/16), 44% in group B (4/9), and 14% in group C (1/7).

EUS was performed prior to EMR in 51 (96%) of the 53 patients with T1b EAC. T staging accuracy (for T1 malignancy) on EUS for pT1b tumors overall was 92%; specifically for pT1sm1 tumors was 92% and for pT1sm2/3 tumors was 92% (Table 3).

**DISCUSSION**

Endoscopic therapy is an alternative to esophagectomy for mucosal EAC in select populations[1] and has been included in national guidelines as a curative form of treatment[16]. More recently, “low risk” T1b EAC have been treated with EET as primary therapy in Germany with recurrence rates ranging from 19% to 28% and estimated five-year survival rates up to 84%[12, 13]. Two small studies from the United States (*n* = 15) and the Netherlands (*n* = 18) showed a recurrence rate of 21% and 17% respectively, with all recurrences in the latter study having initial sm2/3 depth of invasion[14,15].

In our study, we aimed to retrospectively evaluate and compare outcomes of various treatments for T1b EAC after EMR and to evaluate predictors of recurrence after those treatments. We found an overall recurrence rate of 28%, which was not statistically different between those treated with endotherapy alone (38%), chemotherapy, radiation or both (11%) or those undergoing esophagectomy (29%). The overall observed rate of recurrence in our study for those undergoing EET alone is higher than previously reported in patients undergoing EET as primary therapy (Table 4). These differences likely reflect differences in population between most other series (which included primarily low risk T1bsm1 EAC) and our study which evaluated outcomes for all T1b patients. The rate of recurrence in our study does compare favorably to that previously reported for a small cohort of patients with sm2/3 invasion of 33%[14].

We found that most recurrences following EMR in those treated at least partly endoscopically (Groups A and B) were localized. Of the patients who underwent EET alone, there were 6 recurrences (38%), five of which were localized to the esophagus with only 1 having metastatic disease 21 mo following EMR. Of the patients who underwent EET + chemotherapy and/or radiation, 1 (11%) had metastatic recurrence 30 mo after resection. Therefore, EET with or without chemotherapy or radiation, may be a reasonable initial treatment strategy for a subset of patients with T1b EAC, especially those that refuse or are unfit for surgical intervention due to medical comorbidities or home support since most recurrences appear to be localized.

In those that underwent esophagectomy, we identified 2 recurrences out of 7 patients (29%). Our recurrence rate is similar to a recent retrospective study including 26 patients with T1b EAC undergoing surgical resection which showed a 23% recurrence rate[17]. Recurrence or metastatic disease discovered after resection may be related to micrometastatic disease that was unable to be identified prior to esophagectomy.

Overall, we found a 3 year survival rate of 78% and when evaluating the patients in our study; more specifically a rate of 87% in those treated with EET only and 56% in those treated with EET + chemotherapy and/or radiation. When combining those treated at least partly endoscopically, the survival rate at 3 years was 76%. Manner *et al*[13] previously have shown an estimated 5 year survival rate of 84% in those treated with EET with “low risk” T1b. Our lower survival rate is likely reflected in our patient population, as we evaluated all patients with T1b EAC and not only those with “low risk” disease. Tian *et al*[15] reported on a group of patients (*n* = 29) more similar to our cohort including “low risk” and higher risk T1b EAC patients [sm1 (46%) and sm2-3 (54%) invasion] that underwent either EET, chemo/radiation or a combination of both and showed a survival rate of 72% at mean 34.8.

We failed to identify any individual predictors of cancer recurrence in this population. A previous retrospective study with 39 patients with T1b EAC treated with EET alone showed decreased survival in patients with older age and lymphovascular invasion, although it did not specifically assess for predictors of cancer recurrence[18]. In our study, we were unable to identify lymphatic and perineural invasion as predictors of recurrence.

A recent prospective study from Germany evaluated the risk of lymph node metastases when comparing “low risk” (sm1 invasion) to “high risk” (sm2/3 invasion) T1b EAC in patients treated both surgically and with EET, and found a 2% risk of lymph node metastasis in pT1bsm1 tumors and 9% in pT1bsm2/3 tumors, which is lower than has generally been reported in prior studies[19]. In our study which includes both sm1 and sm2/3 invasion, we similarly found 6% of patients with metastatic lymph nodes either on initial staging or on surveillance (one each with sm1 and sm2/3 tumors).

Previous studies have shown excellent accuracy for staging both T1a and T1b esophageal cancers. Specifically, a previous meta-analysis showed good accuracy with area under the curve > 0.93 for both T1a and T1b esophageal cancers[20]. We also demonstrated overall diagnostic accuracy of 91% for pT1 lesions in our cohort.

Our study has several strengths including data from all T1b cancers removed by EMR from two tertiary care referral centers, re-review of all pathology by a single pathologist, and evaluation of outcomes of medical and surgical therapy for these patients. However, our study is limited by the number of patients who refused further therapy or were lost to follow-up which may limit the ability to compare outcomes from various treatments after resection.

In conclusion, our study shows that endoscopic therapy alone following EMR of a T1b cancer is associated with a recurrence rate of 38%. Therefore, treatment with adjuvant therapy appears reasonable in this population when possible. No particular variable is predictive of recurrence following EMR of T1b adenocarcinomas. Therefore, future research into the management and risk stratification of these patients after EMR is warranted.

**COMMENTS**

***Background***

Endoscopic eradication therapy (EET) (including endoscopic mucosal resection and ablative techniques) have become standard of care for high grade dysplasia T1a esophageal cancers. The use of EET for T1b cancers is more controversial due to the higher risk of lymph node involvement and data is lacking.

***Research frontiers***

Recent studies have shown that “low risk” T1b esophageal cancer can be treated safely and effectively with EET. Many of these studies include relatively small numbers of patients, and do not address higher risk T1b esophageal cancers or the use of EET in conjunction with other treatment modalities such as chemotherapy or radiation.

***Innovations and breakthroughs***

In our current study, we attempted to evaluate the clinical outcomes and recurrence rates of T1b esophageal cancers treated with EET alone, as well as those treated with EET in conjunction with chemotherapy and/or radiation as well as those undergoing surgical resection. In addition, we attempted to identify factors that may predict recurrence.

***Applications***

For patients with T1b esophageal cancer and treated with EET alone, the recurrence rate was 38%; therefore treatment with adjuvant therapy in conjunction with EET seems reasonable in patients that are either unable to or refuse to undergo esophagectomy. No particular variables were identified that predict recurrence of cancer in this population following EMR. Further research in these areas regarding management and risk stratification will be required.

***Terminology***

T1b esophageal adenocarcinoma – cancer which invades into but not through the submucosal layer; Endoscopic eradication therapy - Endoscopic treatment including endoscopic mucosal resection and ablative techniques such as radiofrequency ablation and cryotherapy.

***Peer-review***

A retrospective study is reported to investigate outcomes and recurrences of T1b esophageal adenocarcinomas following EMR. The study population consists of 53 patients who underwent EMR in two tertiary centres between 2001 and 2013. Thirty-two of these patients had follow-up longer than 12 months and were included in the analyses. Recurrence developed in 28% of the patients, with the highest percentage (38%) in a subgroup treated with endoscopic procedures alone after the EMR.

**REFERENCES**

1 **Pech O**, May A, Manner H, Behrens A, Pohl J, Weferling M, Hartmann U, Manner N, Huijsmans J, Gossner L, Rabenstein T, Vieth M, Stolte M, Ell C. Long-term efficacy and safety of endoscopic resection for patients with mucosal adenocarcinoma of the esophagus. *Gastroenterology* 2014; **146**: 652-660.e1 [PMID: 24269290 DOI: 10.1053/j.gastro.2013.11.006]

2 **Moss A**, Bourke MJ, Hourigan LF, Gupta S, Williams SJ, Tran K, Swan MP, Hopper AD, Kwan V, Bailey AA. Endoscopic resection for Barrett's high-grade dysplasia and early esophageal adenocarcinoma: an essential staging procedure with long-term therapeutic benefit. *Am J Gastroenterol* 2010; **105**: 1276-1283 [PMID: 20179694 DOI: 10.1038/ajg.2010.1]

3 **Ngamruengphong S**, Wolfsen HC, Wallace MB. Survival of patients with superficial esophageal adenocarcinoma after endoscopic treatment vs surgery. *Clin Gastroenterol Hepatol* 2013; **11**: 1424-1429.e2; quiz e81 [PMID: 23735443 DOI: 10.1016/j.cgh.2013.05.025]

4 **Pech O**, Bollschweiler E, Manner H, Leers J, Ell C, Hölscher AH. Comparison between endoscopic and surgical resection of mucosal esophageal adenocarcinoma in Barrett's esophagus at two high-volume centers. *Ann Surg* 2011; **254**: 67-72 [PMID: 21532466 DOI: 10.1097/SLA.0b013e31821d4bf6]

5 **Das A**, Singh V, Fleischer DE, Sharma VK. A comparison of endoscopic treatment and surgery in early esophageal cancer: an analysis of surveillance epidemiology and end results data. *Am J Gastroenterol* 2008; **103**: 1340-1345 [PMID: 18510606 DOI: 10.1111/j.1572-0241.2008.01889.x]

6 **Dunbar KB**, Spechler SJ. The risk of lymph-node metastases in patients with high-grade dysplasia or intramucosal carcinoma in Barrett's esophagus: a systematic review. *Am J Gastroenterol* 2012; **107**: 850-62; quiz 863 [PMID: 22488081 DOI: 10.1038/ajg.2012.78]

7 **Leers JM**, DeMeester SR, Oezcelik A, Klipfel N, Ayazi S, Abate E, Zehetner J, Lipham JC, Chan L, Hagen JA, DeMeester TR. The prevalence of lymph node metastases in patients with T1 esophageal adenocarcinoma a retrospective review of esophagectomy specimens. *Ann Surg* 2011; **253**: 271-278 [PMID: 21119508 DOI: 10.1097/SLA.0b013e3181fbad42]

8 **Dubecz A**, Kern M, Solymosi N, Schweigert M, Stein HJ. Predictors of Lymph Node Metastasis in Surgically Resected T1 Esophageal Cancer. *Ann Thorac Surg* 2015; **99**: 1879-185; discussion 1886 [PMID: 25929888 DOI: 10.1016/j.athoracsur.2015.02.112]

9 **Bollschweiler E**, Baldus SE, Schröder W, Prenzel K, Gutschow C, Schneider PM, Hölscher AH. High rate of lymph-node metastasis in submucosal esophageal squamous-cell carcinomas and adenocarcinomas. *Endoscopy* 2006; **38**: 149-156 [PMID: 16479422 DOI: 10.1055/s-2006-924993]

10 **Stein HJ**, Feith M, Bruecher BL, Naehrig J, Sarbia M, Siewert JR. Early esophageal cancer: pattern of lymphatic spread and prognostic factors for long-term survival after surgical resection. *Ann Surg* 2005; **242**: 566-73; discussion 573-5 [PMID: 16192817]

11 **Badreddine RJ**, Prasad GA, Lewis JT, Lutzke LS, Borkenhagen LS, Dunagan KT, Wang KK. Depth of submucosal invasion does not predict lymph node metastasis and survival of patients with esophageal carcinoma. *Clin Gastroenterol Hepatol* 2010; **8**: 248-253 [PMID: 19948247 DOI: 10.1016/j.cgh.2009.11.016]

12 **Manner H**, May A, Pech O, Gossner L, Rabenstein T, Günter E, Vieth M, Stolte M, Ell C. Early Barrett's carcinoma with "low-risk" submucosal invasion: long-term results of endoscopic resection with a curative intent. *Am J Gastroenterol* 2008; **103**: 2589-2597 [PMID: 18785950 DOI: 10.1111/j.1572-0241.2008.02083.x]

13 **Manner H**, Pech O, Heldmann Y, May A, Pohl J, Behrens A, Gossner L, Stolte M, Vieth M, Ell C. Efficacy, safety, and long-term results of endoscopic treatment for early stage adenocarcinoma of the esophagus with low-risk sm1 invasion. *Clin Gastroenterol Hepatol* 2013; **11**: 630-65; quiz e45 [PMID: 23357492 DOI: 10.1016/j.cgh.2012.12.040]

14 **Alvarez Herrero L**, Pouw RE, van Vilsteren FG, ten Kate FJ, Visser M, van Berge Henegouwen MI, Weusten BL, Bergman JJ. Risk of lymph node metastasis associated with deeper invasion by early adenocarcinoma of the esophagus and cardia: study based on endoscopic resection specimens. *Endoscopy* 2010; **42**: 1030-1036 [PMID: 20960392 DOI: 10.1055/s-0030-1255858]

15 **Tian J**, Prasad GA, Lutzke LS, Lewis JT, Wang KK. Outcomes of T1b esophageal adenocarcinoma patients. *Gastrointest Endosc* 2011; **74**: 1201-1206 [PMID: 22000793 DOI: 10.1016/j.gie.2011.08.006]

16 **Spechler SJ**, Sharma P, Souza RF, Inadomi JM, Shaheen NJ. American Gastroenterological Association medical position statement on the management of Barrett's esophagus. *Gastroenterology* 2011; **140**: 1084-1091 [PMID: 21376940 DOI: 10.1053/j.gastro.2011.01.030]

17 **Schölvinck D**, Künzli H, Meijer S, Seldenrijk K, van Berge Henegouwen M, Bergman J, Weusten B. Management of patients with T1b esophageal adenocarcinoma: a retrospective cohort study on patient management and risk of metastatic disease. *Surg Endosc* 2016; **30**: 4102-4113 [PMID: 27357927 DOI: 10.1007/s00464-016-5071-y]

18 **Leggett CL**, Lewis JT, Wu TT, Schleck CD, Zinsmeister AR, Dunagan KT, Lutzke LS, Wang KK, Iyer PG. Clinical and histologic determinants of mortality for patients with Barrett's esophagus-related T1 esophageal adenocarcinoma. *Clin Gastroenterol Hepatol* 2015; **13**: 658-64.e1-3 [PMID: 25151255 DOI: 10.1016/j.cgh.2014.08.016]

19 **Manner H**, Pech O, Heldmann Y, May A, Pauthner M, Lorenz D, Fisseler-Eckhoff A, Stolte M, Vieth M, Ell C. The frequency of lymph node metastasis in early-stage adenocarcinoma of the esophagus with incipient submucosal invasion (pT1b sm1) depending on histological risk patterns. *Surg Endosc* 2015; **29**: 1888-1896 [PMID: 25294553 DOI: 10.1007/s00464-014-3881-3]

20 **Thosani N**, Singh H, Kapadia A, Ochi N, Lee JH, Ajani J, Swisher SG, Hofstetter WL, Guha S, Bhutani MS. Diagnostic accuracy of EUS in differentiating mucosal versus submucosal invasion of superficial esophageal cancers: a systematic review and meta-analysis. *Gastrointest Endosc* 2012; **75**: 242-253 [PMID: 22115605 DOI: 10.1016/j.gie.2011.09.016]

**P-Reviewer:** Bossen L, Dobrucali AM, Dinc T, Veitch AM **S-Editor:** Qi Y

**L-Editor: E-Editor:**

**Table 1 Characteristics of T1b esophageal adenocarcinoma by treatment modality following endoscopic mucosal resection**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **Group A (*n* = 16)** | **Group B (*n* = 9)** | **Group C (*n* = 7)** | **Group D (*n* = 21)** | **Overall (*n* = 53)** |
| Average age, yr | 75 ± 78 | 7 0 ± 14 | 62 ± 5 | 72 ± 13 | 71 ± 12 |
| Median follow up after EMR, mo (range) | 34 (12-102) | 27 (12-56) | 49 (13-103) | N/A | 34 (12-103)  (for groups A-C, *n* = 32) |
| EMR Method, *n* (%)  Cap  Band | 6 (38)  10 (62) | 0 (0)  9 (100) | 2 (29)  5 (71) | 4 (19)  17 (81) | 12 (23)  41 (77) |
| Pathology depth, *n* (%)  sm1  sm2/3 | 6 (38)  10 (62) | 4 (44)  5 (56) | 1 (14)  6 (86) | 2 (10)  19 (90) | 13 (25)  40 (75) |
| Tumor Location, *n* (%)  Proximal two-thirds  Distal one-third | 2 (13)  14 (88) | 1 (11)  8 (89) | 1 (14)  6 (86) | 5 (24)  16 (76) | 9 (17)  44 (83) |
| LPI, *n* (%)  Yes  No | 1 (6)  15 (94) | 1 (11)  8 (89) | 0 (0)  7 (100) | 3 (14)  18 (86) | 5 (9)  48 (91) |
| Differentiation, *n* (%)  Well-Moderate  Poor | 14 (88)  2 (13) | 6 (67)  3 (33) | 7 (100)  0 (0) | 15 (71)  6 (29) | 42 (79)  11 (21) |
| EMR margins for cancer, *n* (%)  Deep -/Lateral -  Deep -/Lateral +  Deep +/Lateral +  Deep +/Lateral - | 6 (38)  5 (31)  4 (25)  1 (6) | 2 (22)  1 (11)  6 (66)  0 (0) | 1 (14)  1 (14)  5 (71)  0 (0) | 2 (10)  4 (19)  13 (62)  2 (10) | 11 (21)  11 (21)  28 (53)  3 (6) |
| Recurrences, *n* (%)  Yes  No  Median time to  recurrence (mo,  range) | 6 (38)  10 (63)  21 (6-73) | 1 (11)  8 (88)  30 (30-30) | 2 (29)  5 (71)  21 (7-35) | N/A | 9 (28)  23 (72)  21 (6-73)  (for groups A-C, *n* = 32) |
| Location of recurrence  Local  Metastatic | 5  1 | 0  1 | 1  1 | N/A | 6  3 |

EMR: Endoscopic mucosal resection; LPI: Lymphatic/perineural invasion.

**Table 2 Recurrence rates of esophageal adenocarcinoma by investigated risk factors of EAC (*n* = 32)** ***n* (%)**

|  |  |  |
| --- | --- | --- |
| **Variable** | **Recurrence rates** | ***P* value** |
| EMR method  Cap  Band | 4/8 (50)  5/24 (21) | 0.18 |
| Pathology depth  sm1  sm2/3 | 3/11 (27)  6/21 (29) | 0.11 |
| Tumor Location  Proximal 2/3 esophagus  Distal 1/3 esophagus | 2/4 (50)  7/28 (25) | 0.56 |
| LPI  Yes  No | 0/2 (0)  9/30 (30) | 1.00 |
| Differentiation  Well-moderate  Poor | 8/27 (30)  1/5 (20) | 1.00 |
| Deep EMR margins  Positive  Negative | 4/16 (25)  5/16 (31) | 1.00 |
| Lateral EMR margins  Positive  Negative | 6/22 (27)  3/10 (30) | 1.00 |
| Primary treatment  Endoscopic +/- CRT  Surgical | 7/25 (28)  2/7 (29) | 1.00 |

EMR: Endoscopic mucosal resection; LPI: Lymphatic/perineural invasion; CRT: Chemoradiation.

**Table 3 EUS staging/path accuracy for T1b esophageal adenocarcinoma**

|  |  |  |  |
| --- | --- | --- | --- |
| **EUS staging (*n* = 51)** | **Pathologic staging** | | |
| **pT1sm1 (*n* = 12)** | **pT1sm2/3 (*n* = 39)** | **Overall (all pT1b) (*n* = 51)** |
| uT0 Nx | 0 | 1 | 1 |
| uT1 Nx | 11 | 36 | 47 |
| uT2 Nx | 1 | 2 | 3 |
| T staging accuracy | 91.7% | 92.3% | 92.2% |

**Table 4 Studies evaluating endoscopic management of T1b esophageal adenocarcinoma**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Study** | **# Patients** | **Depth of invasion** | **Histology** | **Margins** | **Remission** | **Recurrence** | **Survival** |
| Manner *et al*[12] 2008 | 21 | sm1 | Well to moderately differentiated, no lymphovascular invasion | Lateral margins negative in 12 | 95% at mean 5.3 mo | 28% at mean 62 months (range 45-89) | 67% estimated 5 yr survival |
| Alvarez Herrero *et al*[14] 2010 | 18 | sm1 and sm2/3 | Well, moderately and poorly differentiated, some with lymphovascular invasion | Not reported | Not reported | 17% | Not reported |
| Tian *et al*[15]  2011 | 29 | sm1 and  sm2-3 | Not reported | Not reported | Not reported | Not reported | 62% with median duration 34.8 mo |
| Manner *et al*[13]  2013 | 66 | sm1 | Well to moderately differentiated, no lymphovascular invasion | Not reported | 84% at mean 4.5 mo | 21% at mean 22 mo (range 6-60) | 84% estimated 5 yr survival |